Repurposing cytarabine for treating primary effusion lymphoma by targeting KSHV latent and lytic replications
M. Gruffaz, S. Zhou, K. Vasan…·S.-J. Gao
This study identifies cytarabine as a potent inhibitor of KSHV-induced primary effusion lymphoma by targeting both viral and host DNA/RNA synthesis and inducing tumor regression in a xenograft model.